CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

CHAPTER 4 GLOBAL EXETER ERLOTINIB HYDROCHLORIDE TABLET MARKET, BY INDICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. PANCREATIC CANCER

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. NON-SMALL CELL LUNG CANCER

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. OTHER CANCERS

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

CHAPTER 5 GLOBAL EXETER ERLOTINIB HYDROCHLORIDE TABLET MARKET, BY REGION

5.1. OVERVIEW
5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast

5.2.3.1. U.S. market size and forecast
5.2.3.2. Canada market size and forecast
5.2.3.3. Mexico market size and forecast

5.2.4. North America Exeter Erlotinib Hydrochloride Tablet Market by Indication

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast

5.3.3.1. Germany market size and forecast
5.3.3.2. France market size and forecast
5.3.3.3. UK market size and forecast
5.3.3.4. Spain market size and forecast
5.3.3.5. Rest of Europe market size and forecast

5.3.4. Europe Exeter Erlotinib Hydrochloride Tablet Market by Indication

5.4. ASIA-PACIFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast

5.4.3.1. Japan market size and forecast
5.4.3.2. China market size and forecast
5.4.3.3. Australia market size and forecast
5.4.3.4. India market size and forecast
5.4.3.5. Rest of Asia-Pacific market size and forecast

5.4.4. Asia-Pacific Exeter Erlotinib Hydrochloride Tablet Market by Indication

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast

5.5.3.1. Brazil market size and forecast
5.5.3.2. Saudi Arabia market size and forecast
5.5.3.3. Turkey market size and forecast
5.5.3.4. South Africa market size and forecast
5.5.3.5. Rest of LAMEA market size and forecast

5.5.4. LAMEA Exeter Erlotinib Hydrochloride Tablet Market by Indication

CHAPTER 9 COMPANY PROFILES

9.1. POLPHARMA PHARMACEUTICAL WORKS

9.1.1. Operating business segments
9.1.2. Business performance
9.1.3. Key strategic moves and developments

9.2. SUANFARMA, NATCO PHARMA

9.2.1. Operating business segments
9.2.2. Business performance
9.2.3. Key strategic moves and developments

9.3. TECOLAND

9.3.1. Operating business segments
9.3.2. Business performance
9.3.3. Key strategic moves and developments

9.4. SHANGHAI BIOSUNDRUG

9.4.1. Operating business segments
9.4.2. Business performance
9.4.3. Key strategic moves and developments

9.5. SHILPA MEDICARE

9.5.1. Operating business segments
9.5.2. Business performance
9.5.3. Key strategic moves and developments

9.6. HEC PHARM

9.6.1. Operating business segments
9.6.2. Business performance
9.6.3. Key strategic moves and developments

9.7. ARASTO PHARMACEUTICAL CHEMICALS

9.7.1. Operating business segments
9.7.2. Business performance
9.7.3. Key strategic moves and developments

9.8. TAVA

9.8.1. Operating business segments
9.8.2. Business performance
9.8.3. Key strategic moves and developments

9.9. ROCHE HOLDING AG

9.9.1. Operating business segments
9.9.2. Business performance
9.9.3. Key strategic moves and developments